Related Experiment Video

Updated: Mar 16, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.8K

Association of IL-6 Promoter and Receptor Polymorphisms with Multiple Myeloma Risk: A Systematic Review and

Yuying Li1, Zhonghua Du1, Xu Wang1

  • 1Cancer Center, First Hospital of Jilin University , Changchun, China .

Genetic Testing and Molecular Biomarkers
|August 16, 2016
PubMed
Abstract

Insights

Genetic variations in interleukin-6 (IL-6) receptor, specifically the IL-6R rs8192284 polymorphism, are linked to an increased risk of multiple myeloma (MM). However, IL-6 promoter variations showed no significant association with MM susceptibility.

Area of Science:

  • Genetics
  • Oncology
  • Immunology

Background:

  • Interleukin-6 (IL-6) is a pleiotropic cytokine implicated in multiple myeloma (MM) pathogenesis.
  • The association between IL-6 genetic variability and MM risk remains unclear.

Purpose of the Study:

  • To investigate the relationship between IL-6 promoter and IL-6 receptor (IL-6R) polymorphisms and the risk of developing MM.
  • To conduct a meta-analysis evaluating IL-6 single-nucleotide polymorphisms (SNPs) and MM susceptibility.

Main Methods:

  • Systematic literature search of multiple databases (PubMed, Cochrane, Embase, CNKI, Wanfang) up to November 2014.
  • Meta-analysis of eight case-control studies for IL-6 promoter polymorphism (rs1800795) and three for IL-6R polymorphism (rs8192284).
  • Results presented as odds ratios (ORs) with 95% confidence intervals (CIs).

Main Results:

  • No significant association was found between the IL-6 promoter rs1800795 (G>C) polymorphism and MM risk.
  • A statistically significant increased risk of MM was associated with the IL-6R rs8192284 (A>C) polymorphism.
  • Subgroup analyses by ethnicity, region, study quality, and Hardy-Weinberg equilibrium confirmed these findings.

Conclusions:

  • The IL-6R rs8192284 (A>C) polymorphism may be associated with an increased risk of multiple myeloma.
  • The IL-6 promoter rs1800795 (G>C) polymorphism does not appear to be significantly linked to MM risk.
  • Larger-scale studies are recommended to validate these findings due to the limited number of studies included.
Keywords:
IL-6 promoterIL-6 receptorSNPsmeta-analysismultiple myeloma

More Related Videos

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Published on: August 21, 2016

13.6K
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.6K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
63
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
94
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
13.9K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.2K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
6.0K